Side-by-side · Research reference
HGH Fragment 176-191vsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED28/59 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
HGH Fragment 176-191
PNC-27
Primary target
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
N/A — does not interact with GH/IGF-1 axis
N/A — cytotoxic mechanism, not signaling modulation
Origin
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
Not reported in available studies
—
02Dosage Protocols
Parameter
HGH Fragment 176-191
PNC-27
Animal dose (IP)
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
—
Human equivalent dose
Not established — no published human RCTs
—
Frequency
Once daily (animal models)
—
Evidence basis
Animal studies only
Pre-clinical / In vitro
Detection window
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
—
Oral bioavailability
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
—
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
HGH Fragment 176-191
PNC-27
Weight gain reduction
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
—
Body fat reduction
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
—
Lipolytic activity
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
—
Insulin sensitivity
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
—
IGF-1 impact
No elevation — fragment does not activate GH/IGF-1 axis
—
Beta-3 AR dependency
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
—
Human evidence
None published — pre-clinical only
—
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
HGH Fragment 176-191
PNC-27
Human safety data
Not available — no published human trials
None available — no human trials conducted
Metabolic profile
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
—
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
PNC-27
—05Administration Protocol
Parameter
HGH Fragment 176-191
PNC-27
1. Route
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Frequency
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Duration
Animal protocols: 14–19 days. Human duration not established — no published trials.
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Storage
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
5. Detection
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
—